Search results for "Mining"
showing 10 items of 1730 documents
Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management
2004
Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management
Primitive neuroectodermal kidney tumor
2002
To the Editor: Primitive neuroectodermal tumors (PNET) and Ewing sarcoma (ES) belong to a group of neoplasms de®ned by neuroectodermal differentiation and a characteristic cytogenetic translocation, t(11;22) (q24;q12) or gene rearrangements between chromosomes 21 and 22 [1]. They are generally aggressive tumors that present as metastatic disease in nearly 50% of the cases. ES is frequently a bone disease, whereas PNET can occur in bones, soft tissues, or any other site. Renal PNETs are extremely rare, with only a few cases reported [2]. We here record an adult with renal PNET and bone metastases at diagnosis. Because these tumor can also be found in children [3] our experience may therefore…
Pancreatic tumors show high levels of hypoxia: regarding Koong et al. IJROBP 2000;48:919–922
2001
In the literature: February 2021
2021
In the literature: December 2020
2021
In the literature: October 2021
2021
In the literature: June 2021
2021
In the literature: April 2021
2021
P08.76 Anti-EGFL7 treatment as an add-on for glioma therapy
2016
Glioblastoma multiforme (GBM) is one the most common and malignant forms of brain tumors. The median survival time of patients diagnosed with primary GBM is around 15 months. In spite of multimodal treatments GBMs remain essentially incurable. Therefore, alternative treatments targeting previously unexplored aspects of GBMs are required. However, the molecular mechanisms underlying the formation of brain tumors have only partially been defined. Especially Notch, a conserved developmental pathway, is promising in terms of GBM formation, as components of this signaling cascade are aberrantly expressed in gliomas. Studies reported that the inhibition of Notch decreased glioma cell proliferatio…
OS1.5 Harnessing soluble LRIG1 for pan-RTK targeting in glioblastoma
2018
INTRODUCTION: The role of receptor tyrosine kinases (RTKs) in glioblastoma is widely acknowledged. However, therapies based on RTK targeting have been continuously unsuccessful in GBM patients, highlighting the complexity of RTK signaling and biology. LRIG1 (Leucine-rich Repeats and ImmunoGlobulin domains protein 1) was identified as an endogenous inhibitor of epidermal growth factor receptor (EGFR) and other RTKs, and was confirmed as a tumor suppressor in various cancer types. We previously identified the soluble form of LRIG1 as a potent inhibitor of GBM growth in vivo, irrespective of EGFR status. Here, we aim to shed light on the molecular mechanisms underlying its anti-cancer activity…